OCUL
Ocular Therapeutix·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OCUL
Ocular Therapeutix, Inc.
A biopharmaceutical company focused on innovative therapies for diseases and conditions of the eye
15 Crosby Drive, Bedford, MA 01730
--
Ocular Therapeutix, Inc., was established in Delaware on September 12, 2006. The company is an integrated biopharmaceutical company focused on developing treatments for retinal diseases and other eye diseases. Its lead drug candidate, AXPAXLI (OTX-TKI), an investigational axitinib intravitreal hydrogel for wet age-related macular degeneration and diabetic retinal disease, is currently in Phase 3 registration trials. The company also commercializes DEXTENZA, an FDA-approved corticosteroid insert for postoperative inflammation and itching, and advances other drug candidates based on its proprietary ELUTYX bioabsorbable hydrogel technology.
Company Financials
EPS
OCUL has released its 2025 Q4 earnings. EPS was reported at -0.29, versus the expected -0.32, beating expectations. The chart below visualizes how OCUL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OCUL has released its 2025 Q4 earnings report, with revenue of 13.25M, reflecting a YoY change of -22.43%, and net profit of -64.65M, showing a YoY change of -33.62%. The Sankey diagram below clearly presents OCUL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
